What Happened?
Cambridge, MA-based Janpix Appointed Roman Fleck as Chief Executive Officer
About the Company
Janpix is discovering and developing monovalent small molecule degraders of Signal Transducer and Activator of Transcription (“STAT”) proteins. Most members of this family of transcription factors have been known for some time and the relevance of STAT3 & STAT5, in particular, in certain cancers is well validated. Although disrupting the function of STAT proteins is very challenging, Janpix has developed new chemistry to address this complex problem.
About the Person
Roman Fleck is Chief Executive Officer at Janpix. Previously, Roman held various senior HR leadership roles in the industry.
Info Source
News
Short Profile